Welcome to LookChem.com Sign In|Join Free

CAS

  • or

132073-82-6

(S)-N-Benzyl-2-hydroxymethylmorpholine is a chiral chemical compound belonging to the morpholine family, characterized by a benzyl group attached to the nitrogen atom and a hydroxymethyl group attached to the carbon atom. It is widely recognized for its role as a building block in the synthesis of pharmaceuticals and agrochemicals, and has been identified as a potential ligand for metal-catalyzed asymmetric transformations. (S)-N-BENZYL-2-HYDROXYMETHYLMORPHOLINE is also known for its use in the synthesis of diverse bioactive molecules and as a reagent in organic chemistry reactions, with ongoing research into its potential application in the development of new drug candidates.

132073-82-6 Suppliers

Post Buying Request

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • 132073-82-6 Structure

  • Basic information

    1. Product Name: (S)-N-BENZYL-2-HYDROXYMETHYLMORPHOLINE
    2. Synonyms: (S)-N-BENZYL-2-HYDROXYMETHYLMORPHOLINE;(S)-4-Benzyl-2-(hydroxymethyl)morpholine;(S)-(4-benzylMorpholin-2-yl)Methanol-HCl;(2S)-4-(PhenylMethyl)-2-MorpholineMethanol
    3. CAS NO:132073-82-6
    4. Molecular Formula: C12H17NO2
    5. Molecular Weight: 207.268880
    6. EINECS: N/A
    7. Product Categories: N/A
    8. Mol File: 132073-82-6.mol

  • Chemical Properties

    1. Melting Point: N/A
    2. Boiling Point: 303.2 °C at 760 mmHg
    3. Flash Point: 137.2 °C
    4. Appearance: /
    5. Density: 1.117 g/cm3
    6. Vapor Pressure: 0.000415mmHg at 25°C
    7. Refractive Index: 1.549
    8. Storage Temp.: Sealed in dry,Room Temperature
    9. Solubility: N/A
    10. PKA: 14.36±0.10(Predicted)
    11. CAS DataBase Reference: (S)-N-BENZYL-2-HYDROXYMETHYLMORPHOLINE(CAS DataBase Reference)
    12. NIST Chemistry Reference: (S)-N-BENZYL-2-HYDROXYMETHYLMORPHOLINE(132073-82-6)
    13. EPA Substance Registry System: (S)-N-BENZYL-2-HYDROXYMETHYLMORPHOLINE(132073-82-6)

  • Safety Data

    1. Hazard Codes: N/A
    2. Statements: N/A
    3. Safety Statements: N/A
    4. WGK Germany:
    5. RTECS:
    6. HazardClass: N/A
    7. PackingGroup: N/A
    8. Hazardous Substances Data: 132073-82-6(Hazardous Substances Data)

132073-82-6 Usage

Uses

Used in Pharmaceutical and Agrochemical Synthesis:
(S)-N-Benzyl-2-hydroxymethylmorpholine is used as a building block for the synthesis of various pharmaceuticals and agrochemicals, leveraging its unique structural features to create novel and effective compounds.
Used in Metal-Catalyzed Asymmetric Transformations:
As a potential ligand, (S)-N-Benzyl-2-hydroxymethylmorpholine is utilized in metal-catalyzed asymmetric transformations, contributing to the development of enantioselective synthetic routes for producing chiral molecules with high purity.
Used in Organic Chemistry Reactions:
(S)-N-BENZYL-2-HYDROXYMETHYLMORPHOLINE serves as a reagent in various organic chemistry reactions, facilitating the synthesis of complex organic molecules and enhancing the efficiency of chemical processes.
Used in the Development of New Drug Candidates:
(S)-N-Benzyl-2-hydroxymethylmorpholine is studied for its potential application in the development of new drug candidates, with ongoing research exploring its bioactivity and therapeutic potential in various medical fields.

Check Digit Verification of cas no

The CAS Registry Mumber 132073-82-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,3,2,0,7 and 3 respectively; the second part has 2 digits, 8 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 132073-82:
(8*1)+(7*3)+(6*2)+(5*0)+(4*7)+(3*3)+(2*8)+(1*2)=96
96 % 10 = 6
So 132073-82-6 is a valid CAS Registry Number.
InChI:InChI=1/C12H17NO2/c14-10-12-9-13(6-7-15-12)8-11-4-2-1-3-5-11/h1-5,12,14H,6-10H2/t12-/m0/s1

132073-82-6SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 14, 2017

Revision Date: Aug 14, 2017

1.Identification

1.1 GHS Product identifier

Product name (S)-4-Benzyl-2-(hydroxymethyl)morpholine

1.2 Other means of identification

Product number -
Other names (S)-4-(phenylmethyl)-2-morpholinemethanol

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:132073-82-6 SDS

132073-82-6Relevant articles and documents

Discovery of substituted pyrazol-4-yl pyridazinone derivatives as novel c-Met kinase inhibitors

Kim, Eun-Young,Kang, Seung-Tae,Jung, Heejung,Park, Chi Hoon,Yun, Chang-Soo,Hwang, Jong Yeon,Byun, Byung Jin,Lee, Chong Ock,Kim, Hyoung Rae,Ha, Jae Du,Ryu, Do Hyun,Cho, Sung Yun

, p. 453 - 464 (2016)

A series of pyridazin-3-one substituted with morpholino-pyrimidine derivatives was synthesized and evaluated as tyrosine kinase inhibitors against c-Met enzyme, and anti-proliferative activities of Hs746T human gastric cancer cell line. Most of compounds exhibited good biological activity, while compound 10, 12a, 14a displayed excellent c-Met enzyme inhibitory activities and Hs746T cell-based activities.

Efficient one-pot synthesis of enantiomerically pure 2-(hydroxymethyl)- morpholines

Breuning, Matthias,Winnacker, Malte,Steiner, Melanie

, p. 2100 - 2106 (2007)

An efficient and convenient one-pot procedure for the synthesis of enantiomerically pure 2-(hydroxymethyl)morpholines with a widely variable substitution pattern was developed. Addition of chiral β-amino alcohols to (S)- or (R)-epichlorohydrin in the pres

Radiosynthesis and evaluation of 18F-labeled dopamine D4-receptor ligands

Willmann, Michael,Ermert, Johannes,Prante, Olaf,Hübner, Harald,Gmeiner, Peter,Neumaier, Bernd

, p. 43 - 52 (2020/08/03)

Introduction: The dopamine D4 receptor (D4R) has attracted considerable attention as potential target for the treatment of a broad range of central nervous system disorders. Although many efforts have been made to improve the performance of putative radioligand candidates, there is still a lack of D4R selective tracers suitable for in vivo PET imaging. Thus, the objective of this work was to develop a D4-selective PET ligand for clinical applications. Methods: Four compounds based on previous and new lead structures were prepared and characterized with regard to their D4R subtype selectivity and predicted lipophilicity. From these, 3-((4-(2-fluorophenyl)piperazin-1-yl)methyl)-1H-pyrrolo[2,3-b]pyridine I and (S)-4-(3-fluoro-4-methoxybenzyl)-2-(phenoxymethyl)morpholine II were selected for labeling with fluorine-18 and subsequent evaluation by in vitro autoradiography to assess their suitability as D4 radioligand candidates for in vivo imaging. Results: The radiosynthesis of [18F]I and [18F]II was successfully achieved by copper-mediated radiofluorination with radiochemical yields of 7% and 66%, respectively. The radioligand [18F]II showed specific binding in areas where D4 expression is expected, whereas [18F]I did not show any uptake in distinct brain regions and exhibited an unacceptable degree of non-specific binding. Conclusions: The compounds studied exhibited high D4R subtype selectivity and logP values compatible with high brain uptake, but only ligand [18F]II showed low non-specific binding and is therefore a good candidate for further evaluation. Advances in knowledge: The discovery of new lead structures for high-affinity D4 ligands opens up new possibilities for the development of suitable PET-radioligands. Implications for patient: PET-imaging of dopamine D4-receptors could facilitate understanding, diagnosis and treatment of neuropsychiatric and neurodegenerative diseases.

Novel Hydrazinone-substituted Pyrimidine Derivatives and Use Thereof

-

Paragraph 0110-0112, (2018/05/29)

The present invention relates to a pyrimidine derivative substituted with novel hydrazine or a pharmaceutically acceptable salt thereof, and to a pharmaceutical composition for inhibiting c-Met tyrosine kinase activity and to a pharmaceutical composition for preventing or treating hyperproliferative disorders, which comprise same as an active ingredient. The present invention can be effectively used as a treatment agent for various hyperproliferative disorders related to excessive cell proliferation and growth caused by abnormal kinase activity, such as cancer, psoriasis, rheumatoid arthritis, and diabetic retinopathy by efficiently inhibiting c-Met tyrosine kinase activity.

Novel Triazolopyrazine Derivatives and Use Thereof

-

Paragraph 0119; 0120, (2017/07/31)

The present invention relates to novel triazolopyrazine derivatives or a pharmaceutically acceptable salt, and a pharmaceutical composition for inhibiting c-Met tyrosine kinase activity and a pharmaceutical composition for preventing or treating hyperproliferative disorders, containing the same as active ingredients. The present invention effectively inhibits c-Met tyrosine kinase activity, thereby being able to be useful as a drug for various hyperproliferative disorders such as cancers, psoriasis, rheumatoid arthritis, diabetic retinitis, etc. related to excessive cell proliferation and growth by abnormal kinase activation.

NOVEL TRIAZOLOPYRAZINE DERIVATIVE AND USE THEREOF

-

Paragraph 0065; 0066; 0067, (2015/10/06)

The present invention relates to a novel triazolopyrazine derivative or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing the same as an active ingredient for preventing or treating hyper proliferative disorder. The present invention can be useful as a therapeutic agent for various hyper proliferative disorders associated with excessive cell proliferation and growth caused by abnormal kinase activity, such as cancer, psoriasis, rheumatoid arthritis, and diabetic retinopathy, by efficiently inhibiting c-Met tyrosine kinase activity.

MORPHOLINO COMPOUNDS, USES AND METHODS

-

Paragraph 0167-0170, (2014/06/11)

The invention relates to morpholino-derivatives according to Formula (I) or stereoisomers or pharmaceutically acceptable salts or solvate thereof, wherein R1, R2, R3, R4, R5, R6, R7/s

Discovery of substituted 6-pheny-3H-pyridazin-3-one derivatives as novel c-Met kinase inhibitors

Kang, Seung-Tae,Kim, Eun-Young,Archary, Raghavendra,Jung, Heejung,Park, Chi Hoon,Yun, Chang-Soo,Hwang, Jong Yeon,Choi, Sang Un,Chae, Chonghak,Lee, Chong Ock,Kim, Hyoung Rae,Ha, Jae Du,Ryu, Dohyun,Cho, Sung Yun

supporting information, p. 5093 - 5097 (2014/12/11)

We report a series of phenyl substituted pyridazin-3-ones substituted with morpholino-pyrimidines. The SAR of the phenyl was explored and their c-Met kinase and cell-based inhibitory activity toward c-Met driven cell lines were evaluated. Described herein

MORPHOLINO COMPOUNDS, USES AND METHODS

-

Page/Page column 47-48, (2012/12/13)

The invention relates to morpholino-derivatives according to Formula (I) or stereoisomers or pharmaceutically acceptable salts or solvate thereof, wherein R1, R2, R3, R4, R5, R6, R7/s

Concise synthesis of (S)-N-BOC-2-hydroxymethylmorpholine and (S)-N-BOC-morpholine-2-carboxylic acid

Henegar, Kevin E.

, p. 3662 - 3665 (2008/09/20)

(Chemical Equation Presented) An operationally simple synthesis of N-BOC-2-hydroxymethylmorpholine (1) and N-BOC-morpholine-2-carboxylic acid (2) from epichlorohydrin has been developed. No chromatography is required in the processing, which allows high p

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 132073-82-6